Drugs / IPH5201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04261075 | Mar 2020 → Jun 2022 | neoplasm | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05742607 | Jun 2023 → Jun 2027 expected | non-small cell lung carcinoma | Innate Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-17 | Innate Pharma | Results Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 innate-pharma.com ↗
The combination of IPH5201 with durvalumab and chemotherapy demonstrated higher pathological complete response (pCR) rates compared with the benchmark set by durvalumab plus chemotherapy alone. |
| 2019-11-06 | Innate Pharma | Results Innate Pharma announces preclinical data presentations at SITC 2019 innate-pharma.com ↗
In vivo data on anti-CD39 IPH5201 supporting the rationale for assessing combination with PD-1/PD-L1 checkpoint inhibitors |
| 2019-05-23 | Innate Pharma | Results Innate Pharma announces publication on next generation immunotherapies targeting the adenosine pathway in “Cell Reports” innate-pharma.com ↗
In vitro and in vivo data support the use of anti-CD39 and anti-CD73 mAbs in combination cancer therapies. |
| 2019-04-01 | Innate Pharma | Results Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting innate-pharma.com ↗
New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway |
All press releases naming this drug 8 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH5201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05742607 ↗ |